HomeNTRA • BMV
add
Natera Inc
Previous close
$3,637.12
Year range
$2,951.26 - $4,568.69
Market cap
28.95B USD
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | 665.50M | 39.79% |
Operating expense | 468.21M | 28.50% |
Net income | 47.26M | 187.89% |
Net profit margin | 7.10 | 162.89% |
Earnings per share | 0.36 | 187.80% |
EBITDA | -12.49M | 79.33% |
Effective tax rate | 454.63% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 1.08B | 11.14% |
Total assets | 2.40B | 44.41% |
Total liabilities | 685.93M | 47.41% |
Total equity | 1.71B | — |
Shares outstanding | 138.34M | — |
Price to book | 293.79 | — |
Return on assets | -2.70% | — |
Return on capital | -3.39% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | 47.26M | 187.89% |
Cash from operations | — | — |
Cash from investing | — | — |
Cash from financing | — | — |
Net change in cash | — | — |
Free cash flow | — | — |
About
Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA testing technology, with a focus on women’s health, cancer, and organ health. Natera’s proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments in San Carlos, California and Austin, Texas. Wikipedia
Founded
Jan 1, 2004
Headquarters
Website
Employees
4,429
